Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 7/20 | 0.37 |
| ▸ | JAK1 | P23458 | 3/20 | 0.37 |
| ▸ | BTK | Q06187 | 6/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CD69 | Q07108 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.35 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.35 |
| ▸ | RIOK1 | Q9BRS2 | 1/20 | 0.35 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.35 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279031 | 0.89 | STK17A (0.43) | EGFRBTK | |
| SCHEMBL4286550 | 0.86 | PAK1 (0.39) | PAK1EGFRJAK2JAK1BTK | |
| SCHEMBL4288730 | 0.83 | EGFR (0.40) | PAK1EGFRJAK2JAK1BTK | |
| SCHEMBL4286546 | 0.83 | EGFR (0.40) | PAK1EGFRJAK2JAK1BTK | |
| SCHEMBL4289496 | 0.83 | JAK2 (0.43) | PAK1EGFRJAK2JAK1JAK3 | |
| SCHEMBL4277090 | 0.83 | JAK2 (0.43) | PAK1EGFRJAK2JAK1JAK3 | |
| SCHEMBL4290703 | 0.81 | EGFR (0.42) | PAK1EGFRJAK2JAK1BTK | |
| SCHEMBL4281774 | 0.81 | EGFR (0.42) | PAK1EGFRJAK2JAK1BTK | |
| SCHEMBL4282357 | 0.81 | EGFR (0.44) | PAK1EGFRJAK2JAK1BTK | |
| SCHEMBL4281832 | 0.81 | EGFR (0.44) | PAK1EGFRJAK2JAK1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309566-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | PAK1 458/4885EGFR 501/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.